Top Analyst Reports for JPMorgan, Novartis & AT&T
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: NASDAQ.COM
Research Reports on Major Stocks: The Zacks Research Daily highlights new reports on 16 significant stocks, including JPMorgan Chase, Novartis, and AT&T, along with insights into micro-cap companies like Perma-Pipe International and Utah Medical Products, emphasizing unique research on smaller firms.
Market Trends and Company Performance: Key findings indicate that JPMorgan is expected to see net interest income growth despite fee income challenges, Novartis benefits from a strong drug portfolio amid competition, and AT&T continues to thrive in the wireless sector while facing challenges in its wireline division.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 161.180
Low
112.00
Averages
127.75
High
143.00
Current: 161.180
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Promethos Capital Exits Entire Position in Sprouts Farmers Market
- Position Liquidation: On February 13, 2026, Promethos Capital sold its entire holding of 34,935 shares in Sprouts Farmers Market, valued at approximately $3.80 million, indicating a significant reduction in confidence and resulting in a decline in the fund's quarter-end position value.
- Poor Market Performance: As of February 13, 2026, Sprouts Farmers Market shares traded at $68.96, reflecting a 60.9% drop over the past year, significantly underperforming the S&P 500 by 73 percentage points, highlighting a decline in the company's competitive position.
- Portfolio Adjustment: The Sprouts Farmers Market position represented 1.02% of Promethos Capital's AUM, and following the liquidation, the fund's top five holdings shifted to include Taiwan Semiconductor and Novartis, indicating a strategic pivot towards other sectors.
- Future Growth Potential: Despite Promethos Capital's exit, Sprouts Farmers Market is actively expanding, aiming for 1,400 locations in the long term, with 70% of its products being attribute-driven, showcasing its differentiated competitive advantage in the health food market.
See More
Goldman Sachs Updates 10-Year Global Equity Forecast
- Optimistic European Outlook: Goldman Sachs projects a 7.5% annual return for European stocks over the next decade, driven by strong earnings growth and a dividend yield of about 3%, which is likely to attract more investor interest in the European market.
- Emerging Market Potential: Emerging market stocks are expected to return 12.8% annually, primarily supported by robust earnings growth in China and India, highlighting the significance and appeal of these markets in the global economy.
- Vanguard ETF Advantages: The Vanguard FTSE Europe ETF boasts an expense ratio of just 0.06%, significantly lower than the average 0.81% for similar funds, providing investors with a cost-effective avenue for European stock exposure, thereby enhancing its market competitiveness.
- US vs. European Stocks: While US stocks outperformed European stocks over the past decade, Goldman believes that due to high valuations in the US market, European stocks may surpass them in the next decade, prompting investors to reassess their asset allocation strategies.
See More
Health Care Stocks Rise as NYSE Index Gains 1.1%
- Strong Performance in Health Care: Health care stocks rose on Friday afternoon, with the NYSE Health Care Index gaining 1.1%, reflecting increased investor confidence in the sector, likely driven by an overall improvement in market sentiment.
- Market Sentiment Recovery: The rise in health care stocks may be correlated with a broader market recovery trend, as investors reassess the investment value of the health care sector after recent volatility, indicating optimism about future growth potential.
- Increased Investor Attention: With ongoing innovations and policy support in the health care industry, investor attention towards health care stocks has significantly increased, potentially attracting more capital into the sector and driving stock prices higher.
- Optimistic Industry Outlook: The growth potential and stability of the health care sector make it attractive amid economic uncertainties, leading investors to view it as a safe haven, further propelling the upward trend in health care stocks.
See More
Novartis Vanrafia Study Results Support Slowing Kidney Function Decline
- Study Overview: Novartis's ALIGN study indicates that Vanrafia (atrasentan) slows the decline of kidney function in IgA nephropathy patients, with a clinically meaningful eGFR change of 2.39 ml/min/1.73m² compared to placebo, highlighting its potential in chronic kidney disease management.
- Accelerated Approval Context: Vanrafia received accelerated approval in April 2025 in the U.S. and China for reducing proteinuria in IgAN patients, with Novartis planning to submit for traditional approval in 2026 to further validate its clinical benefits.
- Long-Term Follow-Up Advantage: The ALIGN study provides the longest follow-up period in pivotal Phase 3 studies for IgAN, ensuring a thorough assessment of Vanrafia's long-term effects, with safety consistent with previous findings, bolstering confidence in its market prospects.
- Market Reaction: Novartis shares rose 0.42% to $161.86 in premarket trading on Friday, nearing its 52-week high of $162.31, reflecting positive market expectations regarding the potential success of the drug.
See More
Novartis' Vanrafia Trial Results Show Significant Kidney Function Improvement
- Clinical Trial Results: Novartis' Vanrafia demonstrated significant kidney function improvement in the phase 3 trial for IgA nephropathy, with a 2.59 mL/min/1.73 m² increase in eGFR compared to placebo at the end of treatment, indicating its potential as a foundational therapy.
- Accelerated Approval Context: Vanrafia received accelerated approval from the FDA last April for proteinuria reduction in IgA nephropathy patients and has recently been granted similar approval in China, highlighting its global market potential.
- Market Performance: Novartis reported a core net income of $17.41 billion for full-year 2025, with earnings per share of $8.98, reflecting an increase from $15.76 billion and $7.81 per share in 2024, showcasing strong performance in drug development and sales.
- Future Plans: Novartis intends to seek traditional approval for Vanrafia this year, further solidifying its market position in kidney disease treatment and laying the groundwork for future revenue growth.
See More
Global Equities Rebound, International ETFs Gain Attention
- International Market Recovery: In 2025, the global market index surged approximately 32%, nearly double the U.S. market benchmark's 17% return, indicating a potential portfolio rotation that has caught investors' attention.
- Strong ETF Performance: The SPDR Portfolio Developed World ex-US ETF climbed over 30% in the past year, holding more than 2,300 developed-market stocks, positioning it prominently within the international recovery narrative while maintaining low fees.
- Currency Dynamics Impact: The weakening U.S. dollar boosted returns for overseas assets, particularly in Europe, where Spain's IBEX 35 index jumped around 50% and Germany's DAX rose about 23%, reflecting the positive effects of fiscal stimulus and a rebound in financial stocks.
- Potential Long-Term Trend: While American tech giants remain dominant, analysts suggest that international equities still trade at a valuation discount, and higher dividend yields abroad strengthen the case for diversification, indicating that the resurgence of international ETFs may represent a durable trend.
See More
Promethos Capital Exits Entire Position in Sprouts Farmers Market
- Position Liquidation: On February 13, 2026, Promethos Capital sold its entire holding of 34,935 shares in Sprouts Farmers Market, valued at approximately $3.80 million, indicating a significant reduction in confidence and resulting in a decline in the fund's quarter-end position value.
- Poor Market Performance: As of February 13, 2026, Sprouts Farmers Market shares traded at $68.96, reflecting a 60.9% drop over the past year, significantly underperforming the S&P 500 by 73 percentage points, highlighting a decline in the company's competitive position.
- Portfolio Adjustment: The Sprouts Farmers Market position represented 1.02% of Promethos Capital's AUM, and following the liquidation, the fund's top five holdings shifted to include Taiwan Semiconductor and Novartis, indicating a strategic pivot towards other sectors.
- Future Growth Potential: Despite Promethos Capital's exit, Sprouts Farmers Market is actively expanding, aiming for 1,400 locations in the long term, with 70% of its products being attribute-driven, showcasing its differentiated competitive advantage in the health food market.
See More
Goldman Sachs Updates 10-Year Global Equity Forecast
- Optimistic European Outlook: Goldman Sachs projects a 7.5% annual return for European stocks over the next decade, driven by strong earnings growth and a dividend yield of about 3%, which is likely to attract more investor interest in the European market.
- Emerging Market Potential: Emerging market stocks are expected to return 12.8% annually, primarily supported by robust earnings growth in China and India, highlighting the significance and appeal of these markets in the global economy.
- Vanguard ETF Advantages: The Vanguard FTSE Europe ETF boasts an expense ratio of just 0.06%, significantly lower than the average 0.81% for similar funds, providing investors with a cost-effective avenue for European stock exposure, thereby enhancing its market competitiveness.
- US vs. European Stocks: While US stocks outperformed European stocks over the past decade, Goldman believes that due to high valuations in the US market, European stocks may surpass them in the next decade, prompting investors to reassess their asset allocation strategies.
See More
Health Care Stocks Rise as NYSE Index Gains 1.1%
- Strong Performance in Health Care: Health care stocks rose on Friday afternoon, with the NYSE Health Care Index gaining 1.1%, reflecting increased investor confidence in the sector, likely driven by an overall improvement in market sentiment.
- Market Sentiment Recovery: The rise in health care stocks may be correlated with a broader market recovery trend, as investors reassess the investment value of the health care sector after recent volatility, indicating optimism about future growth potential.
- Increased Investor Attention: With ongoing innovations and policy support in the health care industry, investor attention towards health care stocks has significantly increased, potentially attracting more capital into the sector and driving stock prices higher.
- Optimistic Industry Outlook: The growth potential and stability of the health care sector make it attractive amid economic uncertainties, leading investors to view it as a safe haven, further propelling the upward trend in health care stocks.
See More
Novartis Vanrafia Study Results Support Slowing Kidney Function Decline
- Study Overview: Novartis's ALIGN study indicates that Vanrafia (atrasentan) slows the decline of kidney function in IgA nephropathy patients, with a clinically meaningful eGFR change of 2.39 ml/min/1.73m² compared to placebo, highlighting its potential in chronic kidney disease management.
- Accelerated Approval Context: Vanrafia received accelerated approval in April 2025 in the U.S. and China for reducing proteinuria in IgAN patients, with Novartis planning to submit for traditional approval in 2026 to further validate its clinical benefits.
- Long-Term Follow-Up Advantage: The ALIGN study provides the longest follow-up period in pivotal Phase 3 studies for IgAN, ensuring a thorough assessment of Vanrafia's long-term effects, with safety consistent with previous findings, bolstering confidence in its market prospects.
- Market Reaction: Novartis shares rose 0.42% to $161.86 in premarket trading on Friday, nearing its 52-week high of $162.31, reflecting positive market expectations regarding the potential success of the drug.
See More
Novartis' Vanrafia Trial Results Show Significant Kidney Function Improvement
- Clinical Trial Results: Novartis' Vanrafia demonstrated significant kidney function improvement in the phase 3 trial for IgA nephropathy, with a 2.59 mL/min/1.73 m² increase in eGFR compared to placebo at the end of treatment, indicating its potential as a foundational therapy.
- Accelerated Approval Context: Vanrafia received accelerated approval from the FDA last April for proteinuria reduction in IgA nephropathy patients and has recently been granted similar approval in China, highlighting its global market potential.
- Market Performance: Novartis reported a core net income of $17.41 billion for full-year 2025, with earnings per share of $8.98, reflecting an increase from $15.76 billion and $7.81 per share in 2024, showcasing strong performance in drug development and sales.
- Future Plans: Novartis intends to seek traditional approval for Vanrafia this year, further solidifying its market position in kidney disease treatment and laying the groundwork for future revenue growth.
See More
Global Equities Rebound, International ETFs Gain Attention
- International Market Recovery: In 2025, the global market index surged approximately 32%, nearly double the U.S. market benchmark's 17% return, indicating a potential portfolio rotation that has caught investors' attention.
- Strong ETF Performance: The SPDR Portfolio Developed World ex-US ETF climbed over 30% in the past year, holding more than 2,300 developed-market stocks, positioning it prominently within the international recovery narrative while maintaining low fees.
- Currency Dynamics Impact: The weakening U.S. dollar boosted returns for overseas assets, particularly in Europe, where Spain's IBEX 35 index jumped around 50% and Germany's DAX rose about 23%, reflecting the positive effects of fiscal stimulus and a rebound in financial stocks.
- Potential Long-Term Trend: While American tech giants remain dominant, analysts suggest that international equities still trade at a valuation discount, and higher dividend yields abroad strengthen the case for diversification, indicating that the resurgence of international ETFs may represent a durable trend.
See More
